Personalized regimen for PCSK9 inhibitors: A therapeutic option that maintains efficacy and reduces costs.
J Clin Lipidol
; 12(5): 1324-1325, 2018.
Article
in En
| MEDLINE
| ID: mdl-30057259
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Serine Proteinase Inhibitors
/
Costs and Cost Analysis
/
Precision Medicine
/
PCSK9 Inhibitors
/
Health Resources
Type of study:
Health_economic_evaluation
Limits:
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
J Clin Lipidol
Journal subject:
BIOQUIMICA
/
METABOLISMO
Year:
2018
Document type:
Article